Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trialMasaaki Kondo, Katsuaki Tanaka, Chiaki Okuse et al.|BMC Cancer|2019Cited by 77
<p>Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p>Katsuaki Ogushi, Shin Maeda, Makoto Chuma et al.|Clinical and Experimental Gastroenterology|2020Cited by 55
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinomaJuichi Takada, Wasaburo Koizumi, Hisashi Hidaka et al.|BMC Research Notes|2015Cited by 43
Field practice study of half‐dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysisManabu Morimoto, Katsuaki Tanaka, Kazushi Numata et al.|Hepatology Research|2014Cited by 30
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinomaSatoshi Kobayashi, Manabu Morimoto, Taito Fukushima et al.|BMC Cancer|2022Cited by 12